The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease

Authors

DOI:

https://doi.org/10.12928/pharmaciana.v12i2.21491

Keywords:

blood pressure, candesartan, amlodipine, furosemide, hypertension, CKD

Abstract

Chronic renal disease is significantly increased by hypertension. Controlling blood pressure is critical in hypertensive individuals. Patients who have good blood pressure (BP) control can reduce morbidity and mortality. This study aimed to compare blood pressure reduction of candesartan-amlodipine with the candesartan-furosemide combination in hypertensive patients with chronic renal disease. The study was conducted by a cohort study design. Retrieval of medical record data was carried out prospectively during the period February-April 2019. The blood pressure reduction was assessed by changes in mean systolic and mean diastolic blood pressure and mean diastolic blood pressure and was analyzed statistically with the SPSS program. A total of 54 patients met the inclusion criteria, consisting of 27 patients receiving candesartan-amlodipine combination and 27 patients receiving candesartan-furosemide combination therapy. The results of the sociodemographic characteristics patients were male 30 patients (55.6%), age 56-65 years 24 patients (44.4%), senior high school education level 31 patients (57.4%). Candesartan-amlodipine and candesartan-furosemide combinations both decreased blood pressure in patients. However, the result of the statistical analysis revealed that there was no significant difference in blood pressure decline. (p> 0.05) between the two combinations.

References

Chazova IE, Dongre N, Vigdorchik A V. (2011). Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. Adv Ther, 28(2):134–49.

Chiara T Di, Scaglione A, Corrao S, Argano C, Pinto A, Scaglione R. (2015). Association between low education and higher global cardiovascular risk. J Clin Hypertension, 17(5):332–7.

Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L. (2020). Pharmacotherapy a Pathophysiologic Approach Eleventh Edition. United States: McGraw-Hill Companies.

Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. (2016). Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Hear, 3(2):1–7.

Gradman AH, Basile JN, Carter BL, Bakris GL. (2011). Combination therapy in hypertension. J Clin Hypertension, 13(3):146–54.

Haendra F, Anggara D, Prayitno N. (2013). Factors related to blood pressure in the Telaga Murni Health Center, West Cikarang in 2012. Journal of health science, 5(1):20–5.

James PA, Oparil S, Carter BL, Cushman WC, Himmelfarb CD, Handler J, et al. (2014). Evidence-based guidelines for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 331(5).

Katzung B, Masters S, Trevor A. (2012). Basic & Clinical Pharmacology 12th Edition. United States of America: McGraw- Hill.

Ku E, Lee BJ, Wei J, Weir MR. (2019). Hypertension in CKD : core curriculum 2019. Am J Kidney Dis, 20:1–12.

Lee I Te, Hung YJ, Chen JF, Wang CY, Lee WJ, Sheu WHH. (2012). Comparison of the Efficacy and Safety Profiles of Two Fixed-Dose Combinations of Antihypertensive Agents, Amlodipine/Benazepril Versus Valsartan/Hydrochlorothiazide, in Patients With Type 2 Diabetes Mellitus and Hypertension: A 16-Week, Multicenter, Rando. Clin Ther, 34(8):1735–50.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. (2013). ESH/ESC guidelines for the management of arterial hypertension: the task force for managing arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 34(28):2159–219.

National Heart Foundation of Australia. (2016). Guideline For The Diagnosis and Management of Hypertension In Adults. Melbourne: National Heart Foundation of Australia

Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW, et al. (2016). Hypertension in chronic kidney disease part 1 out-of-office blood pressure monitoring: methods, thresholds, and patterns. Hypertension, 1093–101.

Saad A. (2018). Formulation Science & Bioavailability Pharmacological Parameters Study on Loop Diuretic Drug - Furosemide. J Formul Sci Bioavailab, 2(1):2–4.

Utami AN, Hakim L, Pramantara IDP. (2014). Comparison of Blood Pressure Reduction After Lisinopril Therapy at Bedtime or Morning Time. Journal of Management and Clinical Services, 4(3):151–8.

Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. (2014). Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the international society of hypertension. J Clin Hypertension, 16(1).

Downloads

Published

2022-07-04

Issue

Vol. 12 No. 2 (2022): Pharmaciana

Section

Clinical and Community Pharmacy

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.